STERIS Beats And Raises, But Tariff Refunds And One Big Life Sciences Order Flatter A Quarter With Softer Margins Underneath

STERIS (NYSE: STE) delivered a clean headline beat for its fiscal second quarter. Adjusted earnings of $2.94 per share topped the $2.67 consensus by 10.1% and grew 19.0% year over year. Revenue of $1.589 billion beat the $1.56 billion estimate by 1.8% and rose 8.8%, with constant currency organic growth of 8%, running ahead of the company's reaffirmed 6-7% full-year pace. Management lifted fiscal 2027 adjusted EPS guidance to $11.35-$11.55 from $11.10-$11.30, a range that had held since the fourth quarter of fiscal 2026. The central tension is that a meaningful share of the upside came from items that will not repeat. Strip those out and the quarter looks solid rather than exceptional.

The quality of the beat deserves scrutiny. Tariff refunds added roughly $20 million pre-tax to the quarter. Per the call, adjusted EPS growth falls to about 13% excluding them. The roughly $0.18 of year-to-date refunds is embedded directly in the raised guidance, and management does not expect further material refunds. That accounts for most of the $0.25 increase at the midpoint, leaving a much smaller operational raise. Margins tell a similar story:

• Adjusted gross margin expanded 100 basis points to 45.3%, but refunds contributed about 130 basis points, so the underlying margin was slightly down.
• Healthcare operating margin slipped 110 basis points to 24%. The release attributed this to inflation, lower productivity and investments that offset volume and price gains.
• AST margin fell 60 basis points.

GAAP EPS of $2.19 versus $1.94 also absorbed charges from a second restructuring plan this year. That plan carries about $45 million in charges for only about $9 million of annualized savings and includes an exit from single-use urology scopes.

Beneath the margins, demand indicators improved in several places:

• **Life Sciences** was the standout. Revenue rose 18% organically, capital equipment surged 53%, and the segment posted a record 44.4% margin. Its full-year guide was lifted to 9-10% from 6-7%. Management framed the strength as reshoring and localization finally converting into orders.
• **Healthcare** consumables and service each grew 10%, and the capital backlog climbed to $456 million from just under $400 million at fiscal year-end.
• **AST**, after flagging customer destocking in the prior two quarters, management declared the destocking over and cited better September and October volumes.

The tone on capital demand and procedures was noticeably more confident.

Bears still have legitimate ammunition. AST grew only 5% in the quarter, and its full-year organic guide was cut to 6-7% from 7-8%, a range reaffirmed just one quarter ago. That sits awkwardly beside the declaration that destocking has ended. Life Sciences was boosted by a single order exceeding $10 million that will not recur quarterly, and that segment's $93 million backlog is down year over year. Management also now frames U.S. procedure growth at roughly 3%, down from 'mid single digits' at the fiscal fourth-quarter call, and cited elective deferrals and hospital financial stress. First-half free cash flow fell to $492.5 million from $527.7 million on an inventory build. That follows a full-year free cash flow guide already trimmed to $800 million in the first quarter to fund the $600 million North Carolina chemistry plant.

The forward catalyst is the agreed acquisition of Xodus Medical, which the call analysis also refers to as 'Exodus Medical.' The business is a patient-positioning and safety consumables franchise in the operating room. It reportedly grows in the mid-teens with low-to-mid-50s EBIT margins and is expected to be accretive and debt-funded. Revised guidance including the deal will come after closing, so the current outlook does not yet capture it.

The market setup is more complicated than the surprise implies. Shares have climbed 15.6% since the open after the August report, to $247.91, and sit about 10.4% above the 200-day moving average. Much of the improvement was arguably priced in before this report. Investor sentiment, however, remained slightly negative and essentially unchanged, moving from -0.1385 to -0.1424. That suggests the rally has not been accompanied by broader enthusiasm. Earnings Whispers trend readings lean positive, with sequential growth and AVWAP favorable while price and momentum are neutral.

The bottom line is that STERIS posted a genuine beat with improving order and backlog signals, a far stronger Life Sciences outlook and a high-margin acquisition in the pipeline. But the guidance raise leans heavily on non-recurring tariff refunds, and underlying margins softened. AST was trimmed, the procedure backdrop cooled, and cash generation lagged. With the stock already well above its 200-day average and sentiment still tepid, the next leg depends on whether backlog conversion and Xodus can offset margin pressure without one-time help.

Read our earnings preview for STERIS plc: https://www.earningswhispers.com/article/STE/21944

This earnings review was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.